Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. (December 2014)

• Record Type: Journal Article
• Authors: Czarnecka, Anna M; Kukwa, Wojciech; Kornakiewicz, Anna; Lian, Fei; Szczylik, Cezary
• Is Part Of: Future oncology. Volume 10:Number 15(2014)
• Page Start: 2493
• Page End: 2508
• Publication Date: 2014-12
• Subjects: biomarker -- HIF -- prediction -- prognosis -- renal cancer -- sorafenib -- sunitinib -- VEGF; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.162
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : The natural history of clear cell renal cell cancer is highly unpredictable with various progressors and with populations where small renal masses may be accompanied by metastatic disease. Currently, there is a critical need to determine patient risk and optimize treatment regimes. For these patients, molecular markers may offer significant information in terms of prognostic and predictive values, as well as determination of valid therapeutic targets. Until now, only a few of the many identified clear cell renal cell cancer biomarkers have been clinically validated in large cohorts. And only several biomarkers are integrated in predictive or prognostic models. Therefore, a large cohesive effort is required to advance the field of clear cell renal cell cancer prognostic biomarkers through systematic discovery, verification, validation and clinical implementation.